关键词：美国FDA；孤品药；安全有效；治疗
摘 要：The Global Orphan Drugs market is growing at a steady rate. In 2013, the Americas dominated the market, where the major contribution was from the US, and this trend is expected to continue during the forecast period. The Americas was followed by the EMEA and APAC regions. It is estimated that 6-10 percent of the world's population will suffer from a rare disease at some point in their life. The APAC region's population is nearly two-thirds of the global total, providing a wider pool of people suffering from the rarest diseases. Hence there is a vast opportunity for vendors in this market to expand into the APAC region as the markets in the region should offer great potential to companies developing orphan drugs. The market is expected to witness an improvement in its growth rate and post a CAGR of 7.61 percent during the period 2013-2018.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Market Segmentation by Product Type

07.1 Global Biologic Orphan Drugs Market

Market Size and Forecast

07.2 Global Non-biologic Orphan Drugs Market

Market Size and Forecast

08. Geographical Segmentation

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

16.1 Competitive Scenario

16.1.1 Key News

16.1.2 Mergers and Acquisitions

16.2 Market Share Analysis

16.3 Other Prominent Vendors

17. Top 10 Vendors' Orphan Drug Sales

18. Top 10 Selling Orphan Drugs in 2013

19. Pipeline Snapshot

20. Key Vendor Analysis

20.1 Celgene Corp.

20.1.1 Business Overview

20.1.2 Key Information

20.1.3 SWOT Analysis

20.2 F. Hoffmann La Roche Ltd.

20.2.1 Business Overview

20.2.2 Business Segmentation

20.2.3 Key Information

20.2.4 SWOT Analysis

20.3 Novartis AG

20.3.1 Business Overview

20.3.2 Business Segmentation

20.3.3 Key Information

20.3.4 SWOT Analysis

20.4 Pfizer Inc.

20.4.1 Business Overview

20.4.2 Key Information

20.4.3 SWOT Analysis

20.5 Sanofi S.A.

20.5.1 Business Overview

20.5.2 Business Segmentation

20.5.3 Key Information

20.5.4 SWOT Analysis

21. Other Reports in this Series